Targeting NRF2 can upregulate PHKG2, promote ferritinophagy, enhance radiation-induced mitochondrial dysfunction, and increase NSCLC sensitivity to radiotherapy. The gene discussed is NFE2L2; the disease is non-small cell lung carcinoma.